Lipoprotein(a) and multi-stage atherogenesis: coronary atherosclerosis, cerebrovascular complications and other correlations of Lp(a) and apo(a)
Abstract
A connection of the level of Lp(a) with the presence and extent of atherosclerosis of main arte ries of head was proved. It was demonstrated that this level in the patients who survived stroke is reliably higher than that in the patients from reference groups. A direct connection of low-molecular phe notypes of apo(a) with the presence, extent and development of atherosclerotic affection of carotid arteries was also proved. hypertension is a significant and independent risk factor of coronary heart disease. Other factors of cardiovascular risk including disorders of lipid metabolism, added to arte rial hypertension, increase the probability of the development of coronary heart disease even to the higher extent.
About the Authors
A. V. Tikhonov
RAMS
Russian Federation
Russian Federation
SB RAMS
Research Institute of Therapy
Yu. P. Nikitin
RAMS
Russian Federation
Russian Federation
SB RAMS
Research Institute of Therapy
References
1. Berg K. A new serum type system in man: the Lp system // Acta Path Microbiol. Scand. 1963. Vol. 59. P. 369–382.
2. Hegele R., Wu L., Williams R. Lipoprotein(a) and plas minogen: linkage analysis / Ed. A. Scanu // Lipoprotein(a): 25 years of progress. N.Y.: Academic Press Inc, 1990. P. 129–139.
3. Scanu A. M., Nakajima K., Edelstein C. Apoli po protein(a): structure and biology // Front Biosci. 2001. Vol. 1, N 6. D. 546–554. Review.
4. Mbevvu A. D., Dumngton P. N. Lipoprotein(a): structure, properties and possible involvement in thrombogenesis and atherogenesis // Atherosclerosis. 1990. Vol. 85. P. 1–14
5. Sing C., Schultz J., Shreffler D. The genetic of the Lp-antigen. II. A family study and proposed models of genetic control // Ann. Hum. Genet. 1974. Vol. 38. P. 47–56.
6. Ober C., Nord A. S., Thompson E. E. et al. Genomewide association study of plasma lipoprotein(a) levels identifies multiple genes on chromosome 6q // J. Lipid. Res. 2009. Vol. 50, N 5. P. 798–806.
7. Utermann G. The mysteries of lipoprotein(a) // Science. 1989. Vol. 246. P. 904–910.
8. Scanu A. M. Lp(a) lipoprotein-coping with heterogeneity // New Eng. J. Med. 2003. Vol. 349. P. 2089–2090.
9. Thomas H. P., Steinhagen-Thiessen E. Lipoprotein(a): Aspects of pathophysiology, epidemiology and treatment // Z. Kardiol. 2003. B. 92 (Suppl 3). T. III. S. 53–58. Review.
10. Koschinsky M. L. Novel insights into Lp(a) physiology and pathogenicity: more questions than answers? // Cardiovasc. Hematol. Disord. Drug. Targets. 2006. Vol. 6, N 4. P. 267–278. Review.
11. Morrisett J., Guyton J., Gaubatz J., Gotto A. Lipoprotein(a): structure, metabolism and epidemiology // Plasma lipoproteins / Ed. A. Gotto. Amsterdam: Elsevier Science Publ., 1987. P. 129–150.
12. Fless G. M. Cellular binding and degradation of lipoprotein(a) // J. Atheroscler. Thromb. 1995. Vol. 2. Suppl 1. S. 1–4. Review.
13. Takahashi A., Taniguchi T. et al. Effects of lipo protein(a) and low density lipoprotein on growth of mitogen-stimulated human umbilical vein endothelial cells // Atherosclerosis. 1996. Vol. 120, N 1-2. P. 93–99.
14. Hrzenjak A., Frank S., Wo X. et al. Galactose-specific asialoglycoprotein receptor is involved in lipoprotein(a) catabolism // Biochem. J. 2003. Vol. 15, 376 (Pt 3). P. 765–771.
15. Morrisett J., Gaybatz J., Knapp R., Guevara J. Structural properties of apo(a): a major apoprotein of human Lp(a) // Lipoprotein(a): 25 years of progress / Ed. A. Scanu. N. Y.: Academic Press Inc., 1990. P. 53–74.
16. Лякишев А. А. Липопротеид(а) как фактор риска развития атероcклероза / А. А. Лякишев, С. Н. Покровский, М. В. Ежов // Обзор. Тер. архив. – 2001. – № 9. – С. 82–88.
17. Luc G., Bard J. M., Arveiler D. et al. PRIME Study Group. Lipoprotein(a) as a predictor of coronary heart disease: the PRIME Study // Atherosclerosis. 2002. Vol. 163, N 2. P. 377–384.
18. Imhof A., Rothenbacher D. et al. Plasma lipoprotein Lp(a), markers of haemostasis and inflammation, and risk and severity of coronary heart disease // Eur. J. Car diovasc. Prev. Rehabil. 2003. Vol. 10, N 5. P. 362–370.
19. Bogavac-Stanojevic N., Djurovic S. et al. Circulating trans forming growth factor-beta1, lipoprotein(a) and cellular adhesion molecules in angiographically assessed coronary artery disease // Clin. Chem. Lab. Med. 2003. Vol. 41, N 7. P. 893–898.
20. Stefoni S., Cianciolo G., Donati G. et al. Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients // Kidney Int. 2002. Vol. 61, N 1. P. 324–335.
21. de Rijke Y. B., Jürgens G. et al. In vivo fate and scavenger receptor recognition of oxidized lipoprotein(a) isoforms in rats // J. Lipid. Res. 1992. Vol. 33, N 9. P. 1315–1325.
22. Harpel P. C., Haque N. S. Chemokine receptor-8: potential role in atherogenesis // Isr. Med. Assoc. J. 2002. Vol. 4, N 11. P. 1025–1027. Review.
23. Haque N. S., Zhang X., French D. L. et al. CC chemokine I-309 is the principal monocyte chemoattractant induced by apolipoprotein(a) in human vascular endothelial cells // Circulation. 2000. Vol. 15, 102 (7). P. 786–792.
24. Pati U., Pati N. Lipoprotein(a), atherosclerosis, and apolipoprotein(a) gene polymorphism // Mol. Genet. Metab. 2000. Vol. 71, N 1-2. P. 87–92. Review.
25. Ezov M. V., Afanasieva O. I., Adamova L. et al. Lipoprotein(a) levels predict myocardial infarction in yang men // Aterosclerosis. 2000. Vol. 51, N 1. P. 304.
26. Диагностика и коррекция нарушений липидного обмена с целью профилактики и лечения атеросклероза. – Российские рекомендации Комитета экспертов Всероссийского научного общества кардиологов. – М.: Медицина, 2004. – 36 с.
27. Тихонов А. В. Генетические аспекты гетерогенности липопротеидов плазмы крови человека / А. В. Тихонов; под ред. Ю. П. Никитина // Вопросы атерогенеза. – Новосибирск, 2005. – С. 137–179.
28. Murase T., Okubo M., Amemiya-Kudo M. et al. Impact of markedly elevated serum lipoprotein(a) levels (> or = 100 mg/dL) on the risk of coronary heart disease // Metabolism. 2007. Vol. 56, N 9. P. 1187–1191.
29. Clarke R., Peden J. F., Hopewell J. C. et al. PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease // N. Engl. J. Med. 2009. Vol. 24; 361 (26). P. 2518–2528.
30. Fibrinogen Studies Collaboration. J. Danesh, S. Lewington, S. G. Thompson et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis // JAMA. 2005. Vol. 12; 294(14). P. 1799–1809.
31. Zlatohlávek L., Zídková K., Vrablík M. et al. Lipoprotein(a) and its position among other risk factors of athe rosclerosis // Physiol. Res. 2008. Vol. 57, N 5. P. 777–783.
32. Emerging Risk Factors Collaboration. Di Angelantonio E., Sarwar N., Perry P. et al. Major lipids, apolipoproteins, and risk of vascular disease // JAMA. 2009. Vol. 11; 302 (18). P. 1993–2000.
33. Prospective Studies Collaboration. Lewington S., Whitlock G., Clarke R. et al. // Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths // Lancet. 2008. Vol. 26; 372 (9635). P. 292–302. Review.
34. Boyer H., deGennes J. L., Truffert J. et al. Lp(a) levels in different types of dyslipidemia in the French population // Atherosclerosis. 1990. Vol. 85. P. 61–69.
35. Ежов М. В. Связь липопротеида(а) и фенотипа апобелка(а) с атеросклерозом у мужчин с ишемической болезнью сердца / М. В. Ежов [и др.] // Тер. архив. – 2000. – № 1. – С. 28–32.
36. Yano Y., Shimokawa K., Okada Y. et al. Immunolocalization of lipoprotein(a) in wounded tissues // J. Histochem. Cytochem. 1997. Vol. 45, N 4. P. 559–568.
37. Cobbaert C., Louisa A., Struijk L. et al. Lipoprotein(a) changes during and after coronary artery bypass grafting: an epiphenomenon? // Ann. Clin. Biochem. 1998. Vol. 35 (Pt 1). P. 75–79.
38. Bittner V., Hardison R., Kelsey S. F. et al. Non-High-Density Lipoprotein Cholesterol Levels Predict Five-Year Outcome in the Bypass Angioplasty Revascularization Investigation (BART) // Circulation. 2002. Vol. 106. P. 2537–2542.
39. Klausen I. C., Beusiegel-Ridker P. M., Hennekens C. H., Stampfer M. J. A prospective study of lipoprotein(a) and risk of myocardial infarction // JAMA. 1993. Vol. 270. P. 2195–2199.
40. Postorino G., Altavilla R., Guerrini M., Forconi S. The association of serum lipoprotein(a) levels with myo cardial infarction and ictus cerebri in the elderly // Arch. Gerontol. Geriatr. 1996. Vol. 22. Suppl 1. P. 213–216.
41. Stubs P., Seedt M., Lanet D. et al. Lipoprotein(a) as a risk predictor for cardiac mortality in patients with acute coronary syndromes // Eur. Heart. J. 1998. Vol. 19. P. 1355–1364.
42. Saku K., Zhang B., Liu R. et al. Associations among serum lipoprotein(a) levels, apolipoprotein(a) phenotypes, and myocardial infarction in patients with extremely low and high levels of serum lipoprotein(a) // Jpn. Circ. J. 1999. Vol. 63, N 9. P. 659–665.
43. Real J. T., Ascaso J. F., Chaves F. J. et al. Plasma Lp(a) values in familial hypercholesterolemia and its relation to coronary heart disease // Nutr. Metab. Cardiovasc. Dis. 1999. Vol. 9, N 1. P. 41–44.
44. Berglund L. Diet and drug therapy for lipoprotein(a) // Curr. Opin. Lipidol. 1995. Vol. 6. P. 48–56.
45. Masana L., Farinaro E., De Henauw S., Nicaud V. Blood pressure in young adults with and without a paternal history of premature coronary heart disease in Europe: the EARS Study. European Arteriosclerosis Study // J. Hum. Hypertens. 1996. Vol. 10, N 4. P. 207–213.
46. Gudnason V., Kakko S., Nicaud V. et al. Cholesteryl ester transfer protein gene effect on CETP activity and plasma high-density lipoprotein in European populations. The EARS Group // Eur. J. Clin. Invest. 1999. Vol. 29, N 2. P. 116–128.
47. Тихонов А. В. Особенности распределения концентрации липопротеидов низкой плотности и показателей липидного обмена среди пожилых жителей Чукотки и Западной Сибири / А. В. Тихонов // Цитология. – 1994. – Т. 36, № 7. – С. 754–755.
48. Nikitin Yu. P., Tikhonov A. V., Grigorieva I. N. Plasma lipoprotein(a) levels and apo(a) isoforms in native population of Сhukotka with and without arterial hypertension // Int. J. Circumpolar Health. 2001. Vol. 60. P. 116–121.
49. Mancilha-Carvalho J. J., Crews D. E. Lipid profiles of Yano mamo Indians of Brazil // Prev. Med. 1990. Vol. 19, N 1. P. 66–75.
50. Marcovina S. M., Kennedy H., Bittolo Bon G. et al. Fish intake, independent of apo(a) size, accounts for lower plasma lipoprotein(a) levels in Bantu fishermen of Tanzania: The Lugalawa Study // Arterioscler. Thromb. Vasc. Biol. 1999. Vol. 19, N 5. P. 1250–1256.
51. Kestin M., Rouse I. L., Correll R. A., Nestel P. J. Cardiovascular disease risk factors in free-living men: comparison of two prudent diets, one based on lactoovovegetarianism and the other allowing lean meat // Am. J. Clin. Nutr. 1989. Vol. 50, N 2. P. 280–287.
52. Richter V., Rassoul F., Hentschel B. et al. Age-dependence of lipid parameters in the general population and vegetarians // Z. Gerontol. Geriatr. 2004. Vol. 37, N 3. P. 207–213.
53. Dahlen G. H., Guyton J. R., Attar M. et al. Association of levels of lipoprotein Lp(a), plasma lipids, and other lipoproteins with coronary artery disease documented by angiography // Circulation. 1986. Vol. 74. P. 758–765.
54. Chopra V., Vasisht S., Gulati S., Manchanda S. C. Serum levels of lipoprotein (a) and other lipids in angiographically defined coronary artery disease patients and healthy blood bank donors // Indian J. Med. Sci. 2000. Vol. 54, N 7. P. 284–289.
55. Berglund L., Ramakrishnan R. Lipoprotein(a): an elusive cardiovascular risk factor // Arterioscler. Thromb. Vasc. Biol. 2004. Vol. 24, N 12. P. 2219–2226. Review.
56. Brown S. A., Morrisett J. D., Boerwinkle E. et al. The relation of lipoprotein(a) concentrations and apolipoprotein(a) phenotypes with asymptomatic atherosclerosis in subjects of the Atherosclerosis Risk in Communities (ARIC) Study // Arterioscler. Thromb. 1993. Vol. 12. P. 1558–1568.
57. Peynet J., Beaudeux J. L., Woimant F. et al. Apolipoprotein(a) size polymorphism in young adults with ischemic stroke // Atherosclerosis. 1999. Vol. 142, N 1. P. 233–239.
58. Rifai N., Ma J., Sacks F. M. et al. Apolipoprotein(a) size and lipoprotein(a) concentration and future risk of angina pectoris with evidence of severe coronary atherosclerosis in men: The Physicians’ Health Study // Clin. Chem. 2004. Vol. 50, N 8. P. 1364–1371.
59. Dahlen G. H. Incidence of Lp(a) lipoprotein among populations // Lipoprotein(a): 25 Years in Progress / Ed. A. M. Scanu. N. Y.: Academic Press. Inc, 1990. P. 151–173.
60. Longenecker J. C., Coresh J., Klag M. J. et al. Lipoprotein(a) level as a predictor of cardiovascular disease and small apoliprotein(a) isoforms in dialysis patients: assay-related differences are important // Clin. Chim. Acta. 2008. Vol. 397, N 1-2. P. 36–41.
61. Kronenberg F., Trenkwalder E., Utermann G. et al. LDL-unbound apolipoprotein(a) and carotid atherosclerosis in hemodialysis patients // Clin. Genet. 1997. Vol. 52, N 5. P. 377–386.
62. Willeit J., Kiechl S., Santer P. et al. Lipoprotein(a) and asymptomatic carotid artery disease. Evidence of a prominent role in the evolution of advanced carotid plaques: the Bruneck Study // Stroke. 1995. Vol. 26. P. 1582–1587.
63. Lupattelli G., Siepi D., Pasqualini L. et al. Lipoprotein(a) in peripheral arterial occlusive disease // Vasa. 1994. Vol. 23, N 4. P. 321–324.
64. Catalano M., Cortelazzo A., Yilmaz Y. et al. The LPA gene C93T polymorphism influences plasma lipoprotein(a) levels and is independently associated with susceptibility to peripheral arterial disease // Clin. Chim. Acta. 2008. Vol. 387, N 1-2. P. 109–112.
65. Hahmann H. W., Schätzer-Klotz D., Bunte T. et al. The significance of high levels of lipoprotein (a) compared with established risk factors in premature coronary artery disease: differences between men and women // Atherosclerosis. 1999. Vol. 144, N 1. P. 221–228.
66. Бритарева В. В. Липопротеид(а) и изоформы апо(а) у больных с перемежающейся хромотой / В. В. Бритарева [и др.] // Тер. архив. – 2002. – № 12. – С. 49–52.
67. Lindholt J. S., Heegaard N. H., Vammen S. et al. Smoking, but not lipids, lipoprotein(a) and antibodies against oxidised LDL, is correlated to the expansion of abdominal aortic aneurysms // Eur. J. Vasc. Endovasc. Surg. 2001. Vol. 21, N 1. P. 51–56.
68. Chen X. F., Tang L. J., Jiang J. J. et al. Increased levels of lipoprotein(a) in non-smoking aortic dissection patients // Clin. Exp. Med. 2008. Vol. 8, N 2. P. 123–127.
69. Tello-Montoliu A., Roldän V., Climent V. E. et al. Does smoking status influence the effect of physical exercise on fibrinolytic function in healthy volunteers? // J. Thromb. Thrombolysis. 2006. Vol. 21, N 2. P. 163–166.
70. Агапов А. А. Результаты коронарного шунтирования на фоне дислипопротеидемии / А. А. Агапов [и др.] // Ангиология и сосудистая хирургия. – 1996. – № 1. – С. 88–97.
71. Ezhov M. V., Lyakishev A. A., Afanasieva O. I. et al. High lipoprotein(a) and low-molecular weight apo(a) phenotypes predispose to coronary occlusions // Atherosclerosis. 2007. Vol. 8 (t). 150A.
72. Ежов М. В. Связь повышенного уровня липопротеида(а) с рестенозом и прогрессированием атеросклероза после чрескожных коронарных вмешательств / М. В. Ежов [и др.] // Кардиоваскулярная терапия и профилактика. – 2009. – Т. 8, № 6. – С. 126.
73. Berglund L., Ramakrishnan R. Lipoprotein(a) An Elusive Cardiovascular Risk Factor // Arterioscler. Thromb. Vasc. Biol. 2004. Vol. 24. P. 2219.
74. Skinner J. S., Farrer M., Albers C. J. et al. Serum Lp(a) lipoprotein concentration is not associated with clinical and angiographic outcome five years after coronary artery bypass graft surgery // Heart. 1997. Vol. 78, N 2. P. 131–135.
75. Yamamoto H., Imazu M., Yamabe T. et al. Risk factors for restenosis after percutaneous transluminal coronary angioplasty: role of lipoprotein(a) // Am. Heart. J. 1995. Vol. 130. P. 1168–1173.
76. Daida H., Lee Y. J., Yokoi H. et al. Prevention of restenosis after percutaneous transluminal coronary angioplasty (PTCA) by reducing lipoprotein(a) levels with low-density lipoprotein apheresis. Low-Density Lipoprotein Apheresis Angioplasty Restenosis Trial (L-ART) Group // Am. J. Cardiol. 1994. Vol. 73. P. 1037–1040.
77. Netea R. T., Netea M. G., Bredie S. J. et al. Lipoprotein(a) concentrations in patients with familial combined hyperlipidemia and hypertension // Neth. J. Med. 1999. Vol. 55, N 1. P. 39–45.
78. Antonicelli R., Testa R., Marcovina S. M. et al. Relationship between lipoprotein(a) levels, oxidative stress, and blood pressure levels in patients with essential hypertension // Clin. Exp. Med. 2001. Vol. 1, N 3. P. 145–150.
79. Lewington S., Clarke R., Qizilbash N. et al. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies // Lancet. 2003. Vol. 22, N 361 (9362). P. 1060–1070.
80. Sechi L. A., De Marchi S. Relationship of lipoprotein(a) to variables of coagulation in hypertensive subjects // J. Investig. Med. 2001. Vol. 49, N 1. P. 12–20.
81. Бритарева В. В. Липопротеид(а) и ишемическая болезнь сердца у больных гипертонической болезнью / В. В. Бритарева [и др.] // Кардиология. – 2002. – № 5. – С. 4–8.
82. Prospective Studies Collaboration / Lewington S., Whit lock G., Clarke R. et al. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths // Lancet. 2008. Vol. 26, N 372 (9635). P. 292–302. Review.
83. Shlipak M. G., Simon J. A., Vittinghoff E. et al. Estrogen and Progestin, lipoprotein(a), and Risk of Recurrent Coronary Heart Disease Events After Menopause // JAMA. 2000. Vol. 283. P. 1845–1852.
84. Коновалов Г. А. Экстракорпоральные методы в лечении тяжелых форм атеросклероза, метаболического синдрома и дилатационной кардиомиопатии / Г. А. Коновалов [и др.] // Кремлевская медицина. – 2001. – Т. 4. – С. 48–54.
85. Bambauer R., Schiel R., Latza R. Low density lipoprotein apheresis in treatment of hyperlipidemia: experience with four different technologies // Ther. Apher. 2000. Vol. 4, N 3. P. 213–217.
86. Thompson G. R. LDL apheresis // Atherosclerosis. 2003. Vol. 167, N 1. P. 1–13. Review.
87. Stefanutti C., Vivenzio A., Di Giacomo S. et al. Treatment of symptomatic hyperLp(a) lipidemia with LDL-apheresis vs. usual care // Transfus. Apher. Sci. 2010. Vol. 42, N 1. P. 21–26.
88. Bambauer R., Schiel R., Latza R. Low-density lipoprotein apheresis: an overview // Ther. Apher. Dial. 2003. Vol. 7, N 4. P. 382–390.
89. Kostner K., Gupta S. Niacin: a lipid polypill? // Expert Opin Pharmacother. 2008. Vol. 9, N 16. P. 2911–2920.
90. Kostner K. M., Kostner G. M. Therapy of hyper-Lp(a) // Handb. Exp. Pharmacol. 2005. Vol. 170. P. 519–536. Review.
91. Braun L. T., Davidson M. H. Lp-PLA2: A new target for statin therapy // Curr. Atheroscler. Rep. 2010. Vol. 12, N 1. P. 29–33.
Review
For citations:
Tikhonov A.V., Nikitin Yu.P. Lipoprotein(a) and multi-stage atherogenesis: coronary atherosclerosis, cerebrovascular complications and other correlations of Lp(a) and apo(a). Ateroscleroz. 2010;6(1):34-42. (In Russ.)
Views:
137
Email this article 